All In MedTech

Device Trial Radar · NCT07428356

Histotripsy for Ablation of Liver Tumours in Asia

Histotripsy Ablation for Liver Tumours (HALT): A Multi-centre Prospective Pilot Study on the Safety and Efficacy of Histotripsy in Asian Primary and Secondary Liver Malignancies

Last checked: Nov 19, 2026Latest source record: Oct 8, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

40

Planned (sponsor's estimate)

Start

Nov 7, 2025

Primary completion

Nov 7, 2027

Study completion May 7, 2029

Sponsor

Lead sponsor
National Cancer Centre, SingaporeAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Feb 23, 2026

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated device
Yes
Who can join
All sexes, from 21 years, up to 99 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The HALT study aims to evaluate histotripsy in an Asian population for both primary (HCC, CCA) and secondary liver malignancies with liver-limited or oligoprogressive disease. In addition to safety and local control, the study incorporates translational endpoints including immune profiling (PBMCs, cytokines), microbiome shifts, and optional tumour biopsies. This trial will provide critical data on the feasibility, tolerability, and biological impact of histotripsy in a region with the highest burden of liver cancer.

Conditions

  • Liver Malignant Tumors

Interventions

  • Histotripsy using HistoSonics Edison™ SystemDevice

    The histotripsy procedure will be performed using the HistoSonics Edison™ System, an image-guided, non-invasive focused ultrasound platform specifically designed for mechanical tissue fractionation. Key steps include general anaesthesia and positioning, pre-treatment planning and imaging, and histotripsy ablation procedure.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. 6-month local control rate.Time frame: 6 months post-procedure.
  2. Major complication rate.Time frame: 30 days post-procedure.

Locations

3 sites in 1 country. Site status is shown where the registry gives one.

  • National University Hospital

    Singapore, Singapore · Recruiting

  • National Cancer Centre Singapore

    Singapore, Singapore · Recruiting

  • Singapore General Hospital

    Singapore, Singapore · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.